Published in Oncotarget on November 01, 2010
To differentiate or not--routes towards metastasis. Nat Rev Cancer (2012) 3.59
EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer (2012) 1.70
Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer. Cell Cycle (2011) 1.34
Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Patholog Res Int (2012) 1.24
Tumour budding: a promising parameter in colorectal cancer. Br J Cancer (2012) 1.22
TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle (2012) 1.15
Proteomic signatures of the desmoplastic invasion front reveal collagen type XII as a marker of myofibroblastic differentiation during colorectal cancer metastasis. Oncotarget (2012) 1.13
Targeting invadopodia to block breast cancer metastasis. Oncotarget (2011) 1.10
Molecular events in primary and metastatic colorectal carcinoma: a review. Patholog Res Int (2012) 1.07
Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study. BMC Cancer (2015) 0.99
Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision. BMC Gastroenterol (2013) 0.98
Combined aberrant expression of E-cadherin and S100A4, but not β-catenin is associated with disease-free survival and overall survival in colorectal cancer patients. Diagn Pathol (2013) 0.95
Role of epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma: is tumor budding the missing link? Front Oncol (2013) 0.95
Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation. Oncotarget (2015) 0.94
Molecular and pathogenetic aspects of tumor budding in colorectal cancer. Front Med (Lausanne) (2015) 0.94
High tumor budding stratifies breast cancer with metastatic properties. Breast Cancer Res Treat (2015) 0.94
Emerging roles of PDGF-D in EMT progression during tumorigenesis. Cancer Treat Rev (2012) 0.93
Expressions of matrix metalloproteinase-9 (MMP-9), dentin sialophosphoprotein (DSPP), and osteopontin (OPN) at histologically negative surgical margins may predict recurrence of oral squamous cell carcinoma. Oncotarget (2012) 0.93
Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients. Br J Cancer (2013) 0.92
Controversies in the pathological assessment of colorectal cancer. World J Gastroenterol (2014) 0.92
Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells. PLoS One (2014) 0.90
Metastatic cancer stem cells: from the concept to therapeutics. Am J Stem Cells (2014) 0.89
Prognostic biomarkers in colorectal cancer: where do we stand? Virchows Arch (2014) 0.87
Organic cation transporter 2 and tumor budding as independent prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy. Int J Clin Exp Pathol (2013) 0.87
TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer. Oncotarget (2015) 0.87
Phenotyping of tumor-associated macrophages in colorectal cancer: Impact on single cell invasion (tumor budding) and clinicopathological outcome. Oncoimmunology (2015) 0.86
Cancer stem cell characteristics, ALDH1 expression in the invasive front of nasopharyngeal carcinoma. Virchows Arch (2013) 0.86
Histopathological features predict metastatic potential in locally advanced colon carcinomas. BMC Cancer (2015) 0.85
The role of nuclear β-catenin accumulation in the Twist2-induced ovarian cancer EMT. PLoS One (2013) 0.85
Tumor budding as a risk factor of lymph node metastasis in submucosal invasive T1 colorectal carcinoma: a retrospective study. BMC Surg (2012) 0.84
Tumor budding in upper gastrointestinal carcinomas. Front Oncol (2014) 0.84
Cell budding from normal appearing epithelia: a predictor of colorectal cancer metastasis? Int J Biol Sci (2013) 0.83
Tumor budding is associated with an increased risk of lymph node metastasis and poor prognosis in superficial esophageal adenocarcinoma. Mod Pathol (2014) 0.83
The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer. Br J Cancer (2015) 0.83
Implications of epithelial-mesenchymal plasticity for heterogeneity in colorectal cancer. Front Oncol (2015) 0.83
Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching. Br J Cancer (2016) 0.81
Lung cancer exosomes as drivers of epithelial mesenchymal transition. Oncotarget (2016) 0.81
Determinants of metastatic competency in colorectal cancer. Mol Oncol (2017) 0.80
The tumor microenvironment: An irreplaceable element of tumor budding and epithelial-mesenchymal transition-mediated cancer metastasis. Cell Adh Migr (2016) 0.80
Recent progress in targeting cancer. Aging (Albany NY) (2011) 0.80
Invasion Types Are Associated With Poor Prognosis in Lung Squamous Carcinoma Patients. Medicine (Baltimore) (2015) 0.79
Single Nucleotide Polymorphisms as Prognostic and Predictive Factors of Adjuvant Chemotherapy in Colorectal Cancer of Stages I and II. Gastroenterol Res Pract (2016) 0.79
Tumor budding in colorectal carcinoma assessed by cytokeratin immunostaining and budding areas: possible involvement of c-Met. Cancer Sci (2014) 0.79
The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Br J Cancer (2016) 0.78
Tumor budding, a novel prognostic indicator for predicting stage progression in T1 bladder cancers. Cancer Sci (2016) 0.78
Absence of myeloperoxidase and CD8 positive cells in colorectal cancer infiltrates identifies patients with severe prognosis. Oncoimmunology (2015) 0.78
Invasion pattern and histologic features of tumor aggressiveness correlate with MMR protein expression, but are independent of activating KRAS and BRAF mutations in CRC. Virchows Arch (2014) 0.78
Norepinephrine induced epithelial-mesenchymal transition in HT-29 and A549 cells in vitro. J Cancer Res Clin Oncol (2015) 0.78
Tumour budding in colorectal cancer: what do we know and what can we do? Virchows Arch (2015) 0.77
Role of intra- and peritumoral budding in the interdisciplinary management of rectal cancer patients. Int J Surg Oncol (2012) 0.77
Clinicopathologic, molecular, and prognostic implications of the loss of EPCAM expression in colorectal carcinoma. Oncotarget (2016) 0.77
ASF-4-1 fibroblast-rich culture increases chemoresistance and mTOR expression of pancreatic cancer BxPC-3 cells at the invasive front in vitro, and promotes tumor growth and invasion in vivo. Oncol Lett (2016) 0.77
Cell type- and tumor zone-specific expression of pVEGFR-1 and its ligands influence colon cancer metastasis. BMC Cancer (2015) 0.77
Combined evaluation of hexokinase 2 and phosphorylated pyruvate dehydrogenase-E1α in invasive front lesions of colorectal tumors predicts cancer metabolism and patient prognosis. Cancer Sci (2014) 0.77
Tumour budding with and without admixed inflammation: two different sides of the same coin? Br J Cancer (2016) 0.76
DAPK loss in colon cancer tumor buds: implications for migration capacity of disseminating tumor cells. Oncotarget (2015) 0.75
DcR3 induces epithelial-mesenchymal transition through activation of the TGF-β3/SMAD signaling pathway in CRC. Oncotarget (2016) 0.75
S100A8(+) stroma cells predict a good prognosis and inhibit aggressiveness in colorectal carcinoma. Oncoimmunology (2016) 0.75
Molecular mechanisms underlying the antitumor activity of (E)-N-hydroxy-3-(1-(4-methoxyphenylsulfonyl)-1,2,3,4-tetrahydroquinolin-6-yl)acrylamide in human colorectal cancer cells in vitro and in vivo. Oncotarget (2015) 0.75
A new simple morphology-based risk score is prognostic in stage I/II colon cancers. Cancer Med (2016) 0.75
KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer. Oncotarget (2016) 0.75
Prognostic significance of tumor budding and single cell invasion in gastric adenocarcinoma. Onco Targets Ther (2017) 0.75
High-Grade Tumor Budding Stratifies Early-Stage Cervical Cancer with Recurrence Risk. PLoS One (2016) 0.75
Tumor budding and laminin5-γ2 in squamous cell carcinoma of the external auditory canal are associated with shorter survival. Springerplus (2015) 0.75
Vascular Invasion and Stromal S100A4 Expression at the Invasive Front of Colorectal Cancer are Novel Determinants and Tumor Prognostic Markers. J Cancer (2017) 0.75
Poorly Differentiated Clusters in Colorectal Adenocarcinomas Share Biological Similarities with Micropapillary Patterns as well as Tumor Buds. J Korean Med Sci (2017) 0.75
The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82
CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02
CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol (2003) 9.13
Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer (2005) 9.04
Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol (2005) 8.15
Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A (2001) 7.99
The role of epithelial-mesenchymal transition in cancer pathology. Pathology (2007) 5.16
EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest (2009) 4.41
Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A (1999) 4.35
The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology (1986) 3.70
Morphology of sporadic colorectal cancer with DNA replication errors. Gut (1998) 3.11
Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs (2005) 3.10
Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum (1993) 2.92
Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol (1986) 2.80
Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol (2007) 2.78
Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res (2006) 2.73
Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology (2002) 2.68
Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology (2004) 2.66
CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res (2003) 2.48
Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology (2007) 2.39
ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene (2010) 2.25
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res (1995) 1.93
Tumour budding in colorectal carcinoma. Histopathology (2007) 1.93
Gastrointestinal stem cells in development and cancer. J Pathol (2009) 1.73
The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin D1, and p16INK4A and is a region of low proliferation. Am J Pathol (2001) 1.73
Cross-talk of WNT and FGF signaling pathways at GSK3beta to regulate beta-catenin and SNAIL signaling cascades. Cancer Biol Ther (2006) 1.68
Prognostic significance of CXCL12 expression in patients with colorectal carcinoma. Am J Clin Pathol (2009) 1.66
Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol (2009) 1.63
Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum (2008) 1.61
The morphological and molecular features of the epithelial-to-mesenchymal transition. Nat Protoc (2009) 1.60
An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer (1989) 1.59
beta(III)-tubulin at the invasive margin of colorectal cancer: possible link to invasion. Virchows Arch (2009) 1.52
Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med (2009) 1.48
Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Mod Pathol (2007) 1.45
Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology (2005) 1.34
TMPRSS4 induces invasion and epithelial-mesenchymal transition through upregulation of integrin alpha5 and its signaling pathways. Carcinogenesis (2010) 1.30
Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology (2009) 1.30
A new prognostic staging system for rectal cancer. Ann Surg (2004) 1.26
Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum (2003) 1.25
APC mutation and tumour budding in colorectal cancer. J Clin Pathol (2003) 1.24
Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer. J Pathol (2007) 1.22
Predictors of extrahepatic recurrence after resection of colorectal liver metastases. Br J Surg (2004) 1.20
Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. Int J Cancer (2011) 1.20
Altered expression and function of E-cadherin in cervical intraepithelial neoplasia and invasive squamous cell carcinoma. J Pathol (1995) 1.19
Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors. World J Gastroenterol (2009) 1.17
Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn J Cancer Res (2001) 1.16
Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells. J Cell Sci (2010) 1.14
Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer. Hepatogastroenterology (2005) 1.14
Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum (2005) 1.11
Pathological prognostic factors predicting lymph node metastasis in submucosal invasive (T1) colorectal carcinoma. Mod Pathol (2010) 1.11
Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-beta pathway. Eur J Cancer (2007) 1.10
Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer (2001) 1.08
Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and long-term prognosis. Dis Colon Rectum (2005) 1.08
Tumor budding as a prognostic marker in stage-III rectal carcinoma. Int J Colorectal Dis (2007) 1.05
Possible contribution of CD44 variant 6 and nuclear beta-catenin expression to the formation of budding tumor cells in patients with T1 colorectal carcinoma. Cancer (2001) 1.05
Risk factors for occult lymph node metastasis of colorectal cancer invading the submucosa and indications for endoscopic mucosal resection. Dis Colon Rectum (2007) 1.03
Tumour budding at invasive margins and outcome in colorectal cancer. Colorectal Dis (2008) 1.03
Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma. J Surg Oncol (2003) 1.03
Newer pathologic assessment techniques for colorectal carcinoma. Clin Cancer Res (2007) 1.02
Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers. Histopathology (2011) 0.97
Aberrant expression of human ortholog of mammalian enabled (hMena) in human colorectal carcinomas: implications for its role in tumor progression. Int J Oncol (2009) 0.96
Increased epidermal growth factor receptor expression at the invasive margin is a negative prognostic factor in colorectal cancer. Int J Cancer (2011) 0.96
Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type. J Clin Pathol (2006) 0.96
Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Oncogene (1997) 0.95
Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer. Histopathology (2009) 0.95
Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res (2008) 0.94
Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World J Gastroenterol (2010) 0.93
Budding invasive margin and prognosis in colorectal cancer--no direct association with beta-catenin expression. Eur J Cancer (2006) 0.93
A novel classification of tumour budding in colorectal cancer based on the presence of cytoplasmic pseudo-fragments around budding foci. Histopathology (2005) 0.93
Differential prognostic significance of morphologic invasive markers in colorectal cancer: tumor budding and cytoplasmic podia. Dis Colon Rectum (2006) 0.93
Epithelial-mesenchymal transition and colorectal cancer: gaining insights into tumor progression using LIM 1863 cells. Cells Tissues Organs (2007) 0.93
The depth of tumor invasion beyond the outer border of the muscularis propria as a prognostic factor for T3 rectal/rectosigmoid cancer. Anticancer Res (2008) 0.92
CD44V6 expression in human colorectal carcinoma. Hum Pathol (1998) 0.92
ABCG5-positivity in tumor buds is an indicator of poor prognosis in node-negative colorectal cancer patients. World J Gastroenterol (2010) 0.91
Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma. Pathol Res Pract (2006) 0.90
Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. Hum Pathol (2009) 0.90
Tumour budding, uPA and PAI-1 are associated with aggressive behaviour in colon cancer. J Surg Oncol (2010) 0.90
Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancer. Histopathology (2010) 0.90
Coexpression of matrilysin and laminin-5 gamma2 chain may contribute to tumor cell migration in colorectal carcinomas. Dig Dis Sci (2003) 0.89
Novel snail1 target proteins in human colon cancer identified by proteomic analysis. PLoS One (2010) 0.88
MMP-9 and cathepsin B expression in tumor budding as an indicator of a more aggressive phenotype of colorectal cancer (CRC). Anticancer Res (2006) 0.88
Tumour budding detected by laminin-5 {gamma}2-chain immunohistochemistry is of prognostic value in epidermoid anal cancer. Ann Oncol (2005) 0.87
Budding (sprouting) as a useful prognostic marker in colorectal mucinous carcinoma. Jpn J Clin Oncol (2002) 0.87
Differences in loss of p16INK4 protein expression by promoter methylation between left- and right-sided primary colorectal carcinomas. Int J Oncol (2003) 0.87
Pathologic prognostic factors in the recurrence of rectal cancer. Clin Colorectal Cancer (2002) 0.86
Expression of adhesion molecules in hepatic metastases of colorectal carcinoma: relationship to primary tumours and prognosis after hepatic resection. J Gastroenterol Hepatol (1999) 0.85
Oncogenic RAS alters the global and gene-specific histone modification pattern during epithelial-mesenchymal transition in colorectal carcinoma cells. Int J Biochem Cell Biol (2010) 0.85
Tumor budding and survival after potentially curative resection of node-positive colon cancer. Dis Colon Rectum (2010) 0.85
Long-term results of curative resection of "minimally invasive" colorectal cancer. Dis Colon Rectum (1995) 0.84
Laminin-5 gamma2 chain expression as a possible determinant of tumor aggressiveness in T1 colorectal carcinomas. Dig Dis Sci (2003) 0.83
Concurrent EGFr and Cox-2 expression in colorectal cancer: proliferation impact and tumour spreading. Ann Oncol (2005) 0.83
Arrest of cell proliferation in budding tumor cells ahead of the invading edge of colonic carcinomas. A preliminary report. Anticancer Res (2008) 0.82
Tumor budding and evidence-based treatment of T2 rectal carcinomas. J Surg Oncol (2005) 0.82
Transforming growth factor beta can be a parameter of aggressiveness of pT1 colorectal cancer. World J Gastroenterol (2005) 0.81
p16(INK4a) promoter methylation and 9p21 allelic loss in colorectal carcinomas: relation with immunohistochemical p16(INK4a) expression and with tumor budding. Hum Pathol (2006) 0.81
Actual number of tumor budding as a new tool for the individualization of treatment of T1 colorectal carcinomas. J Gastroenterol Hepatol (2006) 0.80
Proposed objective criteria for "grade 3" in early invasive colorectal cancer. Am J Clin Pathol (2010) 0.78
Frequent EpCam protein expression in human carcinomas. Hum Pathol (2004) 4.94
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet (2004) 2.44
Prevalence of KIT expression in human tumors. J Clin Oncol (2004) 2.40
Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol (2006) 2.17
Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer (2010) 2.08
High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer (2010) 1.96
Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? Int J Cancer (2010) 1.41
Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol (2012) 1.38
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med (2013) 1.31
Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J Pathol (2011) 1.24
Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression. Clin Cancer Res (2008) 1.23
Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am J Clin Pathol (2007) 1.22
Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer. Hum Pathol (2011) 1.18
Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors. World J Gastroenterol (2009) 1.17
Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer (2010) 1.16
Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. Int J Cancer (2010) 1.16
The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. Eur J Cancer (2010) 1.15
Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. Mod Pathol (2007) 1.13
Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer (2008) 1.12
Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-beta pathway. Eur J Cancer (2007) 1.10
Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol (2012) 1.10
Diagnostic reproducibility of tumour budding in colorectal cancer: a multicentre, multinational study using virtual microscopy. Histopathology (2012) 1.05
Next-generation tissue microarray (ngTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types. J Transl Med (2013) 1.04
Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol (2007) 1.04
RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis. Clin Cancer Res (2008) 1.04
Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol (2003) 1.03
Local recurrence in mismatch repair-proficient colon cancer predicted by an infiltrative tumor border and lack of CD8+ tumor-infiltrating lymphocytes. Clin Cancer Res (2008) 1.02
Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. Int J Cancer (2013) 1.02
Scoring of p53, VEGF, Bcl-2 and APAF-1 immunohistochemistry and interobserver reliability in colorectal cancer. Mod Pathol (2006) 1.01
Patterns of gene amplification in gastrointestinal stromal tumors (GIST). Lab Invest (2005) 0.99
High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor. PLoS One (2013) 0.97
Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer. Mod Pathol (2012) 0.97
Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers. Histopathology (2011) 0.97
Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer. Eur J Cancer (2007) 0.96
Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer. Histopathology (2009) 0.95
TIA-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of CD8 in mismatch repair-proficient colorectal cancer. PLoS One (2010) 0.95
The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome. Histopathology (2013) 0.94
The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer. Histopathology (2012) 0.94
Co-overexpression of p21 and Ki-67 in head and neck squamous cell carcinoma relative to a significantly poor prognosis. Head Neck (2011) 0.93
Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World J Gastroenterol (2010) 0.93
CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival. J Transl Med (2014) 0.93
ABCG5-positivity in tumor buds is an indicator of poor prognosis in node-negative colorectal cancer patients. World J Gastroenterol (2010) 0.91
Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch (2007) 0.91
Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. Hum Pathol (2009) 0.90
Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancer. Histopathology (2010) 0.90
Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study. Virchows Arch (2015) 0.88
High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin E1. J Pathol (2003) 0.88
Characterization of CDKN2A(p16) methylation and impact in colorectal cancer: systematic analysis using pyrosequencing. J Transl Med (2012) 0.88
Tumor border configuration added to TNM staging better stratifies stage II colorectal cancer patients into prognostic subgroups. Cancer (2009) 0.87
VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal cancer [corrected] patients. Mod Pathol (2011) 0.86
Prognostic value of cell cycle and apoptosis regulatory proteins in mismatch repair-proficient colorectal cancer: a tissue microarray-based approach. Am J Clin Pathol (2007) 0.85
Evaluation of colon cancer histomorphology: a comparison between formalin and PAXgene tissue fixation by an international ring trial. Virchows Arch (2014) 0.85
Stratification and Prognostic Relevance of Jass's Molecular Classification of Colorectal Cancer. Front Oncol (2012) 0.84
Loss of Cdx2 Expression in Primary Tumors and Lymph Node Metastases is Specific for Mismatch Repair-Deficiency in Colorectal Cancer. Front Oncol (2013) 0.84
Metastases and primary tumors around dental implants: A literature review and case report of peri-implant pulmonary metastasis. Quintessence Int (2012) 0.83
Chromosomal instability in gastric mucosa-associated lymphoid tissue lymphomas: a fluorescent in situ hybridization study using a tissue microarray approach. Hum Pathol (2008) 0.82
Role of tumor size in the pre-operative management of rectal cancer patients. BMC Gastroenterol (2010) 0.81
Defined morphological criteria allow reliable diagnosis of colorectal serrated polyps and predict polyp genetics. Virchows Arch (2014) 0.79
Investigation of IL-23 (p19, p40) and IL-23R identifies nuclear expression of IL-23 p19 as a favorable prognostic factor in colorectal cancer: a retrospective multicenter study of 675 patients. Oncotarget (2014) 0.79
Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer. BMC Cancer (2010) 0.79
Construction and validation of a bone marrow tissue microarray. J Clin Pathol (2006) 0.79
Combined histomorphologic and immunohistochemical phenotype to predict the presence of vascular invasion in colon cancer. Dis Colon Rectum (2009) 0.78
Role of intra- and peritumoral budding in the interdisciplinary management of rectal cancer patients. Int J Surg Oncol (2012) 0.77
Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC). J Transl Med (2013) 0.77
Tyrosine kinase receptor B (TrkB) expression in colorectal cancers highlights anoikis resistance as a survival mechanism of tumour budding cells. Histopathology (2014) 0.76
Standardization of whole slide image morphologic assessment with definition of a new application: Digital slide dynamic morphometry. J Pathol Inform (2011) 0.75
Correction: DAPK loss in colon cancer tumor buds: implications for migration capacity of disseminating tumor cells. Oncotarget (2017) 0.75